Soleus Capital Management, L.P.
13F Reported Value
ⓘ$2.9B
Holdings
97
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Soleus Capital Management, L.P. disclosed 97 positions worth $2.9B in its Form 13F-HR for Q2 2026, led by $KRYS (Krystal Biotech, Inc.) at 12.0% of the equity portfolio, followed by $CELC and $TGTX. During the quarter the fund opened 21 new positions and exited 17 — including a new stake in $ERAS and a full exit from $PCVX. The portfolio is most concentrated in Healthcare (99.7% of disclosed assets). All figures are sourced directly from Soleus Capital Management, L.P.’s Form 13F-HR filing with the SEC under CIK 1802630.
AI Fund Analysis
Diversifying
$KRYS
$CELC
$TGTX
$NVCR
$UTHR
$GERN
$ANIP
$KIDS
$PODD$UTHRSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 79.2#47
Quality
$349.1M939,254 sh - —
Quality
$178.3M1,704,318 sh - 69.3#276
Quality
$160.9M2,927,895 sh - 71.3
Quality
$159.7M1,049,000 sh - —
Quality
$150.2M9,913,401 sh - 71.3
Quality
$122.2M225,587 sh - 63.7
Quality
$86.2M1,931,436 sh - 73.9
Quality
$72.1M1,843,504 sh - 72.5
Quality
$71.8M867,760 sh - 29.8
Quality
$68.8M4,393,714 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| Krystal Biotech, Inc.$KRYS | 79.2#47 | $349.1M | 939,254 |
| Celcuity Inc.$CELC | — | $178.3M | 1,704,318 |
| TG THERAPEUTICS, INC.$TGTX | 69.3#276 | $160.9M | 2,927,895 |
| INSULET CORP$PODD | 71.3 | $159.7M | 1,049,000 |
| NovoCure Ltd$NVCR | — | $150.2M | 9,913,401 |
| UNITED THERAPEUTICS Corp$UTHR | 71.3 | $122.2M | 225,587 |
 Inspire Medical Systems, Inc.$INSP | 63.7 | $86.2M | 1,931,436 |
 RIGEL PHARMACEUTICALS INC$RIGL | 73.9 | $72.1M | 1,843,504 |
| ANI PHARMACEUTICALS INC$ANIP | 72.5 | $71.8M | 867,760 |
 Beta Bionics, Inc.$BBNX | 29.8 | $68.8M | 4,393,714 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Soleus Capital Management, L.P.'s 97 positions.
Showing top 10 of 97 holdings.
Sector Allocation
Healthcare
$2.9B
Technology
$9.2M
Full Holdings — Soleus Capital Management, L.P. (Q2 2026)
All 97 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $KRYS | Krystal Biotech, Inc. | $349.1M | 12.0% | -19% | 79.2 |
| 2 | $CELC | Celcuity Inc. | $178.3M | 6.1% | +33% | — |
| 3 | $TGTX | TG THERAPEUTICS, INC. | $160.9M | 5.5% | -27% | 69.3 |
| 4 | $PODD | INSULET CORP | $159.7M | 5.5% | +86% | 71.3 |
| 5 | $NVCR | NovoCure Ltd | $150.2M | 5.2% | -6% | — |
| 6 | $UTHR | UNITED THERAPEUTICS Corp | $122.2M | 4.2% | +21% | 71.3 |
| 7 | $INSP | Inspire Medical Systems, Inc. | $86.2M | 3.0% | +235% | 63.7 |
| 8 | $RIGL | RIGEL PHARMACEUTICALS INC | $72.1M | 2.5% | NEW | 73.9 |
| 9 | $ANIP | ANI PHARMACEUTICALS INC | $71.8M | 2.5% | +6% | 72.5 |
| 10 | $BBNX | Beta Bionics, Inc. | $68.8M | 2.4% | +1% | 29.8 |
| 11 |  $VCEL | Vericel Corp | $64.9M | 2.2% | -43% | 62.8 |
| 12 |  $PRAX | Praxis Precision Medicines, Inc. | $59.4M | 2.0% | -46% | — |
| 13 | $GERN | GERON CORP | $54.8M | 1.9% | +3% | — |
| 14 |  $ALKS | Alkermes plc. | $53.9M | 1.9% | -48% | — |
| 15 |  $ERAS | Erasca, Inc. | $49.5M | 1.7% | NEW | — |
| 16 |  $NPCE | NeuroPace Inc | $46.3M | 1.6% | -1% | 32.4 |
| 17 |  $PGNY | Progyny, Inc. | $46.2M | 1.6% | -22% | 62.7 |
| 18 |  $INDV | Indivior Pharmaceuticals, Inc. | $43.7M | 1.5% | -16% | 58.5 |
| 19 |  $PBLS | Parabilis Medicines, Inc. | $40.1M | 1.4% | NEW | — |
| 20 |  $FOCL | EDAP TMS SA | $37.9M | 1.3% | +0% | 17.8 |
| 21 |  $GMED | GLOBUS MEDICAL INC | $37.0M | 1.3% | -36% | 79.5 |
| 22 |  $RCUS | Arcus Biosciences, Inc. | $36.0M | 1.2% | +159% | 8.5 |
| 23 |  $SNDX | Syndax Pharmaceuticals Inc | $35.6M | 1.2% | -6% | 33.8 |
| 24 |  $NRIX | Nurix Therapeutics, Inc. | $35.5M | 1.2% | +56% | 6.4 |
| 25 |  $LEGN | Legend Biotech Corp | $34.8M | 1.2% | NEW | 47.8 |
| 26 |  $JBIO | Jade Biosciences, Inc. | $34.5M | 1.2% | +95% | — |
| 27 |  $UNH | UNITEDHEALTH GROUP INC | $33.3M | 1.1% | NEW | 62.7 |
| 28 |  $AVTX | Avalo Therapeutics, Inc. | $30.6M | 1.1% | +274% | 11.7 |
| 29 |  $URGN | UroGen Pharma Ltd. | $30.5M | 1.1% | +14% | — |
| 30 |  $MBX | MBX Biosciences, Inc. | $28.4M | 1.0% | +188% | — |
| 31 |  $PALI | PALISADE BIO, INC. | $27.3M | 0.9% | NEW | — |
| 32 |  $PHVS | Pharvaris N.V. | $25.3M | 0.9% | +4% | — |
| 33 |  $ORGO | Organogenesis Holdings Inc. | $24.6M | 0.8% | +1% | 30.4 |
| 34 |  $SUPN | SUPERNUS PHARMACEUTICALS, INC. | $24.2M | 0.8% | NEW | 41.9 |
| 35 |  $PRCT | PROCEPT BioRobotics Corp | $22.6M | 0.8% | +527% | 33.3 |
| 36 |  $TNGX | Tango Therapeutics, Inc. | $22.2M | 0.8% | +58% | 17.6 |
| 37 |  $IKT | Inhibikase Therapeutics, Inc. | $22.1M | 0.8% | +0% | — |
| 38 |  $TRVI | Trevi Therapeutics, Inc. | $22.0M | 0.8% | -27% | — |
| 39 |  $BMRN | BIOMARIN PHARMACEUTICAL INC | $21.5M | 0.7% | -42% | 58.2 |
| 40 |  $LIVN | LivaNova PLC | $21.0M | 0.7% | -56% | — |
| 41 |  $ARGX | ARGENX SE | $18.5M | 0.6% | +470% | — |
| 42 |  $NVCT | Nuvectis Pharma, Inc. | $18.4M | 0.6% | NEW | — |
| 43 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $18.3M | 0.6% | NEW | 13.6 |
| 44 |  $EWTX | Edgewise Therapeutics, Inc. | $18.3M | 0.6% | -69% | — |
| 45 |  $PRLD | Prelude Therapeutics Inc | $18.0M | 0.6% | NEW | 21.5 |
| 46 |  $XENE | Xenon Pharmaceuticals Inc. | $16.1M | 0.6% | -9% | 24 |
| 47 |  $CCCC | C4 Therapeutics, Inc. | $15.8M | 0.5% | -11% | 18.2 |
| 48 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $15.8M | 0.5% | -53% | — |
| 49 | $KIDS | ORTHOPEDIATRICS CORP | $14.0M | 0.5% | +19% | 37.8 |
| 50 |  $AVLN | Avalyn Pharma Inc. | $13.8M | 0.5% | NEW | — |
| 51 |  $BDSX | BIODESIX INC | $13.2M | 0.5% | +41% | 35 |
| 52 |  $SYRE | Spyre Therapeutics, Inc. | $13.1M | 0.5% | NEW | — |
| 53 |  $TWST | Twist Bioscience Corp | $10.8M | 0.4% | -91% | 33.9 |
| 54 |  $VIR | Vir Biotechnology, Inc. | $10.2M | 0.3% | -50% | 38.2 |
| 55 |  $ALNY | ALNYLAM PHARMACEUTICALS, INC. | $9.9M | 0.3% | -75% | 71.4 |
| 56 |  $IMVT | Immunovant, Inc. | $9.7M | 0.3% | +10% | — |
| 57 |  $INSM | INSMED Inc | $9.6M | 0.3% | +780% | 39.4 |
| 58 |  $SEPN | Septerna, Inc. | $9.2M | 0.3% | +0% | 59.2 |
| 59 |  $SOPH | SOPHiA GENETICS SA | $9.0M | 0.3% | -15% | — |
| 60 |  $NKTR | NEKTAR THERAPEUTICS | $9.0M | 0.3% | NEW | 9.7 |
| 61 |  $MIRM | Mirum Pharmaceuticals, Inc. | $8.8M | 0.3% | -81% | 35 |
| 62 |  $AORT | ARTIVION, INC. | $8.7M | 0.3% | NEW | 48.1 |
| 63 |  $TNDM | TANDEM DIABETES CARE INC | $8.7M | 0.3% | -27% | 42.8 |
| 64 |  $ELVN | Enliven Therapeutics, Inc. | $8.4M | 0.3% | -28% | — |
| 65 |  $SION | Sionna Therapeutics, Inc. | $7.8M | 0.3% | -39% | — |
| 66 |  $BLTE | BELITE BIO, INC | $7.8M | 0.3% | NEW | — |
| 67 |  $CERS | CERUS CORP | $7.3M | 0.3% | -77% | 38.5 |
| 68 |  $SLN | Silence Therapeutics plc | $6.9M | 0.2% | NEW | — |
| 69 |  $IMUX | IMMUNIC, INC. | $6.9M | 0.2% | -90% | — |
| 70 |  $IVVD | Invivyd, Inc. | $6.7M | 0.2% | +0% | 29.7 |
| 71 |  $MRK | Merck & Co., Inc. | $6.4M | 0.2% | -75% | 59.9 |
| 72 |  $RLMD | RELMADA THERAPEUTICS, INC. | $5.8M | 0.2% | +0% | — |
| 73 |  $GPCR | Structure Therapeutics Inc. | $5.7M | 0.2% | +34% | — |
| 74 |  $EOLS | Evolus, Inc. | $5.7M | 0.2% | -63% | 39 |
| 75 |  $ANL | Adlai Nortye Group Ltd. | $4.7M | 0.2% | NEW | — |
| 76 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $4.6M | 0.2% | NEW | 11.6 |
| 77 |  $KPTI | Karyopharm Therapeutics Inc. | $4.3M | 0.1% | +0% | 15.1 |
| 78 |  $CNTX | Context Therapeutics Inc. | $3.9M | 0.1% | +1% | — |
| 79 |  $LUNG | Pulmonx Corp | $3.6M | 0.1% | +0% | 23.4 |
| 80 |  $SABS | SAB Biotherapeutics, Inc. | $3.5M | 0.1% | -14% | — |
| 81 |  $TECX | Tectonic Therapeutic, Inc. | $3.5M | 0.1% | -16% | — |
| 82 |  $AXGN | Axogen, Inc. | $2.6M | 0.1% | -92% | 40.8 |
| 83 |  $MSLE | Satellos Bioscience Inc. | $2.4M | 0.1% | -24% | — |
| 84 |  $AVBP | ArriVent BioPharma, Inc. | $1.7M | 0.1% | NEW | — |
| 85 |  $CORT | CORCEPT THERAPEUTICS INC | $1.7M | 0.1% | -93% | 57.8 |
| 86 |  $SLDB | Solid Biosciences Inc. | $1.5M | 0.1% | NEW | — |
| 87 |  $VCYT | VERACYTE, INC. | $1.5M | 0.1% | -92% | 68.6 |
| 88 |  $CGEM | Cullinan Therapeutics, Inc. | $910,500 | 0.0% | -88% | — |
| 89 |  $NSPR | InspireMD, Inc. | $732,100 | 0.0% | +0% | — |
| 90 |  $WGS | GeneDx Holdings Corp. | $686,500 | 0.0% | NEW | 35.4 |
| 91 |  $IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $624,000 | 0.0% | -85% | 36.8 |
| 92 |  $LRMR | Larimar Therapeutics, Inc. | $573,711 | 0.0% | -82% | — |
| 93 |  $CGON | CG Oncology, Inc. | $355,250 | 0.0% | -75% | 27 |
| 94 |  $QNRX | Quoin Pharmaceuticals, Ltd. | $352,013 | 0.0% | +0% | — |
| 95 |  $EQ | Equillium, Inc. | $288,000 | 0.0% | NEW | 11.7 |
| 96 |  $NTRA | Natera, Inc. | $271,450 | 0.0% | -99% | 53.5 |
| 97 |  $NEO | NEOGENOMICS INC | $145,900 | 0.0% | -94% | 34.3 |
New Positions (21)
$ERAS Erasca, Inc.$49.5M$PBLS Parabilis Medicines, Inc.$40.1M$LEGN Legend Biotech Corp$34.8M$UNH UNITEDHEALTH GROUP INC$33.3M$PALI PALISADE BIO, INC.$27.3M$SUPN SUPERNUS PHARMACEUTICALS, INC.$24.2M$NVCT Nuvectis Pharma, Inc.$18.4M$CAPR CAPRICOR THERAPEUTICS, INC.$18.3M$PRLD Prelude Therapeutics Inc$18.0M$AVLN Avalyn Pharma Inc.$13.8M$SYRE Spyre Therapeutics, Inc.$13.1M$NKTR NEKTAR THERAPEUTICS$9.0M$AORT ARTIVION, INC.$8.7M$BLTE BELITE BIO, INC$7.8M$SLN Silence Therapeutics plc$6.9MExited Positions (17)
$PCVX Vaxcyte, Inc.
$ICLR ICON PLC
$TVTX Travere Therapeutics, Inc.
$INBX Inhibrx Biosciences, Inc.
$DXCM DEXCOM INC
$ETON Eton Pharmaceuticals, Inc.
$ARWR ARROWHEAD PHARMACEUTICALS, INC.
$CTMX CytomX Therapeutics, Inc.
$COGT Cogent Biosciences, Inc.
$TYRA Tyra Biosciences, Inc.
$STAA STAAR SURGICAL CO
$ANAB ANAPTYSBIO, INC
$RAPP Rapport Therapeutics, Inc.
$ZYME Zymeworks Inc.
$LBRX LB PHARMACEUTICALS INCBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Soleus Capital Management, L.P. including:
Track Soleus Capital Management, L.P.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Soleus Capital Management, L.P. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Soleus Capital Management, L.P.
13F Pro is an AI hedge fund tracker and stock research platform. For Soleus Capital Management, L.P. (SEC CIK: 1802630), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Soleus Capital Management, L.P.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.